唑来膦酸用于儿童代谢性骨病
Zoledronic acid in pediatric metabolic bone disorders.
作者信息
Bowden Sasigarn A, Mahan John D
机构信息
Division of Endocrinology, Department of Pediatrics, Nationwide Children's Hospital/the Ohio State University College of Medicine, Columbus, Ohio, USA.
Division of Nephrology, Department of Pediatrics, Nationwide Children's Hospital/the Ohio State University College of Medicine, Columbus, Ohio, USA.
出版信息
Transl Pediatr. 2017 Oct;6(4):256-268. doi: 10.21037/tp.2017.09.10.
Abstract
Zoledronic acid (ZA), a highly potent intravenous bisphosphonate (BP), has been increasingly used in children with primary and secondary osteoporosis due to its convenience of shorter infusion time and less frequent dosing compared to pamidronate. Many studies have also demonstrated beneficial effects of ZA in other conditions such as hypercalcemia of malignancy, fibrous dysplasia (FD), chemotherapy-related osteonecrosis (ON) and metastatic bone disease. This review summarizes pharmacologic properties, mechanism of action, dosing regimen, and therapeutic outcomes of ZA in a variety of metabolic bone disorders in children. Several potential novel uses of ZA are also discussed. Safety concerns and adverse effects are also highlighted.
摘要
唑来膦酸（ZA）是一种高效的静脉注射双膦酸盐（BP），由于与帕米膦酸相比，其输注时间更短且给药频率更低，因而在原发性和继发性骨质疏松症儿童中得到越来越多的应用。许多研究还证明了ZA在其他病症中的有益作用，如恶性肿瘤引起的高钙血症、骨纤维发育不良（FD）、化疗相关骨坏死（ON）和转移性骨病。本综述总结了ZA在儿童各种代谢性骨病中的药理特性、作用机制、给药方案和治疗效果。还讨论了ZA几种潜在的新用途。同时也强调了安全问题和不良反应。
相似文献
1
Zoledronic acid in pediatric metabolic bone disorders.
Transl Pediatr. 2017 Oct;6(4):256-268. doi: 10.21037/tp.2017.09.10.
2
Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Bone. 2019 Apr;121:60-67. doi: 10.1016/j.bone.2019.01.003. Epub 2019 Jan 4.
3
Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
J Clin Endocrinol Metab. 2015 Nov;100(11):4163-71. doi: 10.1210/jc.2015-2680. Epub 2015 Aug 26.
4
Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing.
Oncologist. 2019 Feb;24(2):178-184. doi: 10.1634/theoncologist.2018-0218. Epub 2018 Oct 8.
5
EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Endocr Pract. 2019 Jan;25(1):23-30. doi: 10.4158/EP-2018-0328. Epub 2018 Nov 1.
6
Clinical Efficacy of Zoledronic Acid on Fracture Reduction in Youth With Primary and Secondary Skeletal Fragility.
J Clin Endocrinol Metab. 2025 Jun 17;110(7):2031-2040. doi: 10.1210/clinem/dgae661.
7
Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
Arch Endocrinol Metab. 2022 Apr 28;66(2):247-255. doi: 10.20945/2359-3997000000459. Epub 2022 Apr 11.
8
The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Oncologist. 2002;7(6):481-91. doi: 10.1634/theoncologist.7-6-481.
9
Site specific effects of zoledronic acid during tibial and mandibular fracture repair.
PLoS One. 2012;7(2):e31771. doi: 10.1371/journal.pone.0031771. Epub 2012 Feb 16.
10
Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
BJU Int. 2010 Apr;105(8):1082-8. doi: 10.1111/j.1464-410X.2009.08956.x. Epub 2009 Nov 13.
引用本文的文献
1
Diagnosis and Management of Osteoporosis in Children and Adolescents.
Ewha Med J. 2023 Oct;46(4):e18. doi: 10.12771/emj.2023.e18. Epub 2023 Oct 31.
2
Effective Use of Zoledronic Acid for Refractory Hypercalcemia in Neonatal Subcutaneous Fat Necrosis.
Indian J Pediatr. 2024 Dec;91(12):1311. doi: 10.1007/s12098-024-05260-5. Epub 2024 Sep 6.
3
Fatality owing to pulmonary hemorrhage following pamidronate disodium administration in a neonate with osteogenesis imperfecta type 2: A case report.
Clin Pediatr Endocrinol. 2024;33(2):76-81. doi: 10.1297/cpe.2023-0061. Epub 2024 Feb 9.
4
Case Report and Literature Review: Bisphosphonate, Sirolimus, and Atenolol Treatment in a 4-Year-Old Child Diagnosed with Gorham-Stout Disease.
Pharmaceuticals (Basel). 2023 Oct 23;16(10):1504. doi: 10.3390/ph16101504.
5
Interleukin-17 plays a role in dental pulp inflammation mediated by zoledronic acid: a mechanism unrelated to the Th17 immune response?
J Appl Oral Sci. 2023 Oct 9;31:e20230230. doi: 10.1590/1678-7757-2023-0230. eCollection 2023.
6
Pretargeted PET of Osteodestructive Lesions in Dogs.
Mol Pharm. 2022 Sep 5;19(9):3153-3162. doi: 10.1021/acs.molpharmaceut.2c00220. Epub 2022 May 30.
7
Low bone mineral density on DXA and slipped capital femoral epiphysis as rare presentation in a child with Rubinstein-Taybi syndrome.
BMJ Case Rep. 2021 Aug 19;14(8):e242349. doi: 10.1136/bcr-2021-242349.
8
Exploiting the anticancer effects of a nitrogen bisphosphonate nanomedicine for glioblastoma multiforme.
J Nanobiotechnology. 2021 May 4;19(1):127. doi: 10.1186/s12951-021-00856-x.
9
Response to Zoledronic Acid Infusion in Children With Fibrous Dysplasia.
Front Pediatr. 2020 Nov 24;8:582316. doi: 10.3389/fped.2020.582316. eCollection 2020.
10
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer.
Cancer Cell Int. 2019 Feb 8;19:28. doi: 10.1186/s12935-019-0745-x. eCollection 2019.
本文引用的文献
1
Enhanced Osteogenic Differentiation in Zoledronate-Treated Osteoporotic Patients.
Int J Mol Sci. 2017 Jun 13;18(6):1261. doi: 10.3390/ijms18061261.
2
2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Arthritis Rheumatol. 2017 Aug;69(8):1521-1537. doi: 10.1002/art.40137. Epub 2017 Jun 6.
3
Recent advances in the management of osteoporosis.
F1000Res. 2017 May 5;6:625. doi: 10.12688/f1000research.10682.1. eCollection 2017.
4
Life-Threatening Hypercalcemia During Prodrome of Pneumonia in an Immunocompetent Infant.
Glob Pediatr Health. 2017 May 2;4:2333794X17705955. doi: 10.1177/2333794X17705955. eCollection 2017.
5
Effect of single-dose dexamethasone on acute phase response following zoledronic acid: a randomized controlled trial.
Osteoporos Int. 2017 Jun;28(6):1867-1874. doi: 10.1007/s00198-017-3960-0. Epub 2017 Feb 23.
6
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Cochrane Database Syst Rev. 2017 Jan 24;1(1):CD010899. doi: 10.1002/14651858.CD010899.pub2.
7
Zoledronic Acid (Reclast, Aclasta): A Review in Osteoporosis.
Drugs. 2016 Nov;76(17):1683-1697. doi: 10.1007/s40265-016-0662-4.
8
Use of new targeted cancer therapies in children: effects on dental development and risk of jaw osteonecrosis: a review.
J Oral Pathol Med. 2017 May;46(5):321-326. doi: 10.1111/jop.12516. Epub 2016 Nov 14.
9
Use of Zoledronic Acid in Paediatric Craniofacial Fibrous Dysplasia.
Case Rep Pediatr. 2016;2016:2329483. doi: 10.1155/2016/2329483. Epub 2016 Sep 22.
10
Timing of dental development in osteogenesis imperfecta patients with and without bisphosphonate treatment.
Bone. 2017 Jan;94:29-33. doi: 10.1016/j.bone.2016.10.004. Epub 2016 Oct 7.
Zotero 插件